Table 3

Impact of NAI therapy starting at 24 h postinfection in mice infected with a recombinant A/WSN/33 (H1N1) H275Y virusa

Regimen% mortality on day 12 p.i. (n = 8)Mean % wt loss ± SD on day 5 p.i. (n = 11–12)Mean lung viral titer (PFU/ml) ± SD on day 5 p.i. (n = 4)
Uninfected/untreated0***−1.2 ± 1.1***Nd
Untreated-infected7516.9 ± 1.53.66 × 106 ± 0.11 × 106
Oselamivir 5 × 1 mg/kg7514 ± 1.43.0 × 106 ± 0.09 × 106
Oseltamivir 5 × 10 mg/kg0***11.9 ± 1*2.0 × 105 ± 0.44 × 105***
Peramivir 1 × 90 mg/kg0***−0.6 ± 0.9***8.0 × 102 ± 5.29 × 102***
Peramivir 5 × 45 mg/kg0***−1.3 ± 1.1***2.2 × 103 ± 0.6 × 103***
  • a *, P < 0.05; ***, P < 0.001 (versus the untreated group). Statistical significance was determined by using Kaplan-Meier analysis for mortality and the one-way ANOVA test for weight loss and lung viral titers. Nd, not determined. The viral inoculum was 5.7 × 103 PFU.